tradingkey.logo
tradingkey.logo
Search

Eli Lilly and Co

LLY
Add to Watchlist
948.450USD
-26.510-2.72%
Close 05/08, 16:00ETQuotes delayed by 15 min
893.19BMarket Cap
33.63P/E TTM

Eli Lilly and Co

948.450
-26.510-2.72%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Eli Lilly and Co

Currency: USD Updated: 2026-05-08

Key Insights

Eli Lilly and Co's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1195.36.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eli Lilly and Co's Score

Industry at a Glance

Industry Ranking
40 / 156
Overall Ranking
117 / 4494
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Eli Lilly and Co Highlights

StrengthsRisks

Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.

As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."

Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.

The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.

By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.

Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.

High Growth
The company's revenue has grown steadily over the past 3 years, averaging 91.01% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 65.18B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 45.87%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 45.87%.
Undervalued
The company’s latest PE is 33.63, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 800.95M shares, increasing 0.92% quarter-over-quarter.
Held by Manning & Napier Group, LLC
Star Investor Manning & Napier Group, LLC holds 45.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.87.

Analyst Rating

Based on 35 analysts
Buy
Current Rating
1195.362
Target Price
+23.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Eli Lilly and Co is 7.41, ranking 109 out of 156 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 19.80B, representing a year-over-year increase of 55.55%, while its net profit experienced a year-over-year increase of 168.04%.

Score

Industry at a Glance

Previous score
7.41
Change
0

Financials

7.38

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.59

Operational Efficiency

7.40

Growth Potential

7.50

Shareholder Returns

7.20

Eli Lilly and Co's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Eli Lilly and Co is 5.27, ranking 147 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 33.63, which is 304.65% below the recent high of 136.10 and 1.46% above the recent low of 33.14.

Score

Industry at a Glance

Previous score
5.27
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 40/156
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Eli Lilly and Co is 8.06, ranking 57 out of 156 in the Pharmaceuticals industry. The average price target is 1055.00, with a high of 1500.00 and a low of 706.04.

Score

Industry at a Glance

Previous score
8.06
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 35 analysts
Buy
Current Rating
1195.362
Target Price
+23.50%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Eli Lilly and Co
LLY
35
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
Gilead Sciences Inc
GILD
33
1
2
3
...
35

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Eli Lilly and Co is 9.12, ranking 33 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1013.12 and the support level at 867.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.52
Change
-0.4

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(4)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
18.854
Neutral
RSI(14)
52.363
Neutral
STOCH(KDJ)(9,3,3)
77.445
Neutral
ATR(14)
31.924
Low Volatility
CCI(14)
53.800
Neutral
Williams %R
32.906
Buy
TRIX(12,20)
0.092
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
973.452
Sell
MA10
935.867
Buy
MA20
924.639
Buy
MA50
941.780
Buy
MA100
997.538
Sell
MA200
916.322
Buy

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Eli Lilly and Co is 7.00, ranking 47 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 84.76%, representing a quarter-over-quarter increase of 1.57%. The largest institutional shareholder is The Vanguard, holding a total of 78.56M shares, representing 8.34% of shares outstanding, with 0.23% increase in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Lilly Endowment, Inc.
91.90M
-0.32%
The Vanguard Group, Inc.
Star Investors
81.59M
+1.24%
PNC Investments LLC
51.12M
-0.05%
BlackRock Institutional Trust Company, N.A.
41.84M
-0.14%
State Street Investment Management (US)
35.36M
+1.83%
Capital Research Global Investors
24.57M
-2.08%
Fidelity Management & Research Company LLC
24.08M
+6.13%
Geode Capital Management, L.L.C.
19.81M
-0.04%
Capital World Investors
15.03M
+0.41%
1
2

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Eli Lilly and Co is 8.80, ranking 21 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Eli Lilly and Co’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Score

Industry at a Glance

Previous score
8.80
Change
0
Beta vs S&P 500 index
0.48
VaR
+2.80%
240-Day Maximum Drawdown
+23.64%
240-Day Volatility
+34.51%

Return

Best Daily Return
60 days
+9.80%
120 days
+10.33%
5 years
+14.87%
Worst Daily Return
60 days
-5.94%
120 days
-7.79%
5 years
-14.14%
Sharpe Ratio
60 days
-0.68
120 days
-0.20
5 years
+1.06

Risk Assessment

Maximum Drawdown
240 days
+23.64%
3 years
+34.83%
5 years
+34.83%
Return-to-Drawdown Ratio
240 days
+1.39
3 years
+1.05
5 years
+1.64
Skewness
240 days
-0.27
3 years
+0.38
5 years
+0.45

Volatility

Realised Volatility
240 days
+34.51%
5 years
+34.69%
Standardised True Range
240 days
+2.80%
5 years
+1.77%
Downside Risk-Adjusted Return
120 days
-35.87%
240 days
-35.87%
Maximum Daily Upside Volatility
60 days
+32.47%
Maximum Daily Downside Volatility
60 days
+28.52%

Liquidity

Average Turnover Rate
60 days
+0.47%
120 days
+0.45%
5 years
--
Turnover Deviation
20 days
+86.75%
60 days
+25.56%
120 days
+21.57%

Peer Comparison

Pharmaceuticals
Eli Lilly and Co
Eli Lilly and Co
LLY
7.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
CPRX
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC
JAZZ
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
COLL
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
Kiniksa Pharmaceuticals International PLC
KNSA
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc
NBIX
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI